Featured Research

from universities, journals, and other organizations

CD4 count is non-inferior to viral load for treatment switching in adults with HIV

Date:
August 6, 2013
Source:
Public Library of Science
Summary:
For adults infected with HIV in Thailand a monitoring strategy based on CD4 count (a type of white blood cell) is non-inferior to the recommended monitoring strategy measuring the amount of HIV virus in a patient's blood, to determine when to switch from first-line to more costly second-line antiretroviral treatment according to a clinical trial.

For adults infected with HIV in Thailand a monitoring strategy based on CD4 count (a type of white blood cell) is non-inferior to the recommended monitoring strategy measuring the amount of HIV virus in a patient's blood, to determine when to switch from first-line to more costly second-line antiretroviral treatment according to a clinical trial published this week in PLOS Medicine.

The study was conducted by an international team of researchers led by Marc Lallemant from Chiang Mai University, Thailand and the Harvard School of Public Health, United States and provides reassurance for health centres in resource-limited setting using CD4 counts alone to monitor treatment of patients with HIV.

The clinical trial included 716 adult patients with HIV in Thailand who were starting antiretroviral therapy for the first time. The amount of HIV virus in the patients' blood (known as viral load) as well as CD4 count was measured for each patient every 3 months but for patients randomized to one of the clinical trial's arms physicians only had access to CD4 counts to measure response to therapy and determine whether to switch to second-line anti-HIV drugs, whereas the other arm used both viral load and CD4-count to monitor treatment and viral load measurements were used to determine whether to switch antiretroviral drugs or not. The researchers followed-up the patients for three years after they initiated treatment and compared the number of patients with clinical failure (a very low CD4 count, the onset of AIDS, or death) between the two arms. Overall, 58 patients (30 in the viral load arm and 28 in the CD4 count arm) reached the primary endpoint of clinical failure, which meant that the cumulative risk of clinical failure at 3 years was not statistically different between arms using the different monitoring strategies.

The researchers also found that the probability of a treatment switch was similar in the two arms, but the average time from treatment initiation to treatment switch and the average duration of a high viral load after treatment switch were both longer in the CD4 arm than in the viral load arm. Finally, the future-drug option score, a measure of viral drug resistance profiles, was similar in the two arms at the time of treatment switch.

The authors say, "These findings confirm that access to life-saving [antiretroviral] treatment should continue to be expanded even in settings without virological monitoring, and provide reassurance to treatment programs currently based on CD4 monitoring alone, as [viral load] measurement becomes more affordable and feasible in resource limited settings."


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Gonzague Jourdain, Sophie Le Cœur, Nicole Ngo-Giang-Huong, Patrinee Traisathit, Tim R. Cressey, Federica Fregonese, Baptiste Leurent, Intira J. Collins, Malee Techapornroong, Sukit Banchongkit, Sudanee Buranabanjasatean, Guttiga Halue, Ampaipith Nilmanat, Nuananong Luekamlung, Virat Klinbuayaem, Apichat Chutanunta, Pacharee Kantipong, Chureeratana Bowonwatanuwong, Rittha Lertkoonalak, Prattana Leenasirimakul, Somboon Tansuphasawasdikul, Pensiriwan Sang-a-gad, Panita Pathipvanich, Srisuda Thongbuaban, Pakorn Wittayapraparat, Naree Eiamsirikit, Yuwadee Buranawanitchakorn, Naruepon Yutthakasemsunt, Narong Winiyakul, Luc Decker, Sylvaine Barbier, Suporn Koetsawang, Wasna Sirirungsi, Kenneth McIntosh, Sombat Thanprasertsuk, Marc Lallemant. Switching HIV Treatment in Adults Based on CD4 Count Versus Viral Load Monitoring: A Randomized, Non-Inferiority Trial in Thailand. PLoS Medicine, 2013; 10 (8): e1001494 DOI: 10.1371/journal.pmed.1001494

Cite This Page:

Public Library of Science. "CD4 count is non-inferior to viral load for treatment switching in adults with HIV." ScienceDaily. ScienceDaily, 6 August 2013. <www.sciencedaily.com/releases/2013/08/130806203501.htm>.
Public Library of Science. (2013, August 6). CD4 count is non-inferior to viral load for treatment switching in adults with HIV. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/08/130806203501.htm
Public Library of Science. "CD4 count is non-inferior to viral load for treatment switching in adults with HIV." ScienceDaily. www.sciencedaily.com/releases/2013/08/130806203501.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins